Beatrix Lutiger
About
Beatrix Lutiger is a scholar working on Cardiology and Cardiovascular Medicine, Oncology and General Health Professions.
According to data from OpenAlex, Beatrix Lutiger has authored 25 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Cardiology and Cardiovascular Medicine, 8 papers in Oncology and 5 papers in General Health Professions. Recurrent topics in Beatrix Lutiger's work include Heart Failure Treatment and Management (9 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer Treatment and Pharmacology (5 papers). Beatrix Lutiger is often cited by papers focused on Heart Failure Treatment and Management (9 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer Treatment and Pharmacology (5 papers). Beatrix Lutiger collaborates with scholars based in Switzerland, Italy and France. Beatrix Lutiger's co-authors include Michel Komajda, Willem J. Remme, Armin Scherhag, Marco Metra, John G.F. Cleland, Andrea Di Lenarda, Christian Torp‐Pedersen, Karl Swedberg, Philip A. Poole‐Wilson and Peter Hanrath and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Journal of the American College of Cardiology.
In The Last Decade
Beatrix Lutiger
24 papers receiving 1.9k citations
Hit Papers
Peers
Beatrix Lutiger
Armin Scherhag Germany
Andrzej Surdacki Poland
Georg Wensing Germany
Thomas Langenickel Switzerland
George Klinger United States
Emmanuel Androulakis Greece
K. H. Rahn Germany
Michael Böhm Germany
Hajime Nakahama Japan
Mias Pretorius United States
Citations per year, relative to Beatrix Lutiger Beatrix Lutiger (= 1×)
peers
Armin Scherhag
Countries citing papers authored by Beatrix Lutiger
Since
Specialization
Citations
This map shows the geographic impact of Beatrix Lutiger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beatrix Lutiger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beatrix Lutiger more than expected).
Fields of papers citing papers by Beatrix Lutiger
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Beatrix Lutiger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beatrix Lutiger. The network helps show where Beatrix Lutiger may publish in the future.
Co-authorship network of co-authors of Beatrix Lutiger
This figure shows the co-authorship network connecting the top 25 collaborators of Beatrix Lutiger. A scholar is included among the top collaborators of Beatrix Lutiger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beatrix Lutiger. Beatrix Lutiger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Ilhan‐Mutlu, Aysegül, Matthias Osswald, Yunxiang Liao, et al.. (2016). Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma. Molecular Cancer Therapeutics. 15(4). 702–710.
2.
Brandes, Alba A., Warren Mason, Josef Pichler, et al.. (2014). Can Bevacizumab Prolong Survival for Glioblastoma Patients Through Multiple Lines of Therapy?. Future Oncology. 10(7). 1137–1145.
3.
Ahn, Myung‐Ju, R. Gervais, J. Mezger, et al.. (2011). 9112 POSTER AVAPERL1 (MO22089) – Interim Safety of Maintenance (mtc) Bevacizumab (bev) + Pemetrexed (pern) in Patients (pts) With Advanced Non-squamous Non-small Cell Lung Cancer (nsNSCLC) After First-line (1L) Bev-cisplatin (cis)-pem Treatment (Tx). European Journal of Cancer. 47. S626–S626.
4.
Berry, Scott, David Cunningham, M. Michael, et al.. (2006). Preliminary safety of bevacizumab with first-line Folfox, Capox, Folfiri and capecitabine for mCRC—First B.E.A.Trial. Journal of Clinical Oncology. 24(18_suppl). 3534–3534.
5.
Lenarda, Andrea Di, Willem J. Remme, Andrew Charlesworth, et al.. (2005). Exchange of β-Blockers in Heart Failure Patients. Experiences from the Poststudy Phase of COMET (the Carvedilol or Metoprolol European Trial). European Journal of Heart Failure. 7(4). 640–649.
6.
Torp‐Pedersen, Christian, Philip A. Poole‐Wilson, Karl Swedberg, et al.. (2005). Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure—COMET. American Heart Journal. 149(2). 370–376.
7.
Metra, Marco, Christian Torp‐Pedersen, Karl Swedberg, et al.. (2005). Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. European Heart Journal. 26(21). 2259–2268.
8.
Komajda, Michel, Beatrix Lutiger, Hugo Madeira, et al.. (2004). Tolerability of Carvedilol and ACE-Inhibition in Mild Heart Failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN). European Journal of Heart Failure. 6(4). 467–475.
9.
Lenarda, Andrea Di, Philip A. Poole‐Wilson, John G.F. Cleland, et al.. (2004). 1001-26 Exchange of beta-blocking therapy in heart failure patients. Experiences from the post study phase of COMET (the carvedilol or metoprolol European trial). Journal of the American College of Cardiology. 43(5). A7–A7.
10.
Metra, Marco, Philip A. Poole‐Wilson, John G.F. Cleland, et al.. (2004). 835-3 Beta-blocker dose does not influence the beneficial effects of carvedilol compared to metroprolol in the patients with heart failure: Results from the carvedilol or Metoprolol European Trial (COMET). Journal of the American College of Cardiology. 43(5). A206–A206.
11.
Cleland, John G.F., Karl Swedberg, Andrea Di Lenarda, et al.. (2004). 835-4 Comparison of the effects of metoprolol and carvedilol on symptoms, well-being, and quality-adjusted life-years: A description of the patient-journey in COMET. Journal of the American College of Cardiology. 43(5). A206–A206.
12.
Metra, Marco, John G.F. Cleland, Andrea Di Lenarda, et al.. (2004). 1012-121 Lack of heart rate effects on the mortality benefits of carvedilol compared to metoprolol in the patients with heart failure: Results from the carvedilol or metoprolol European trial (COMET). Journal of the American College of Cardiology. 43(5). A157–A157.
13.
Remme, Willem J., John G.F. Cleland, Andrea Di Lenarda, et al.. (2004). 835-2 Carvedilol better protects against vascular events than metoprolol in heart failure: Results from COMET. Journal of the American College of Cardiology. 43(5). A205–A206.
14.
Remme, Willem J., G. Riegger, Per Hildebrandt, et al.. (2004). The Benefits of Early Combination Treatment of Carvedilol and an ACE-Inhibitor in Mild Heart Failure and Left Ventricular Systolic Dysfunction. The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation Trial (CARMEN). Cardiovascular Drugs and Therapy. 18(1). 57–66.
15.
Poole‐Wilson, Philip A., Karl Swedberg, John G.F. Cleland, et al.. (2004). 835-1 A comparison of adverse events occurring with carvedilol or metoprolol in the treatment of heart failure: Results from COMET. Journal of the American College of Cardiology. 43(5). A205–A205.
16.
Remme, Willem J., John G.F. Cleland, Andrea Di Lenarda, et al.. (2004). Consistent survival benefit of carvedilol over metoprolol irrespective of baseline characteristics of heart failure patients – mode of death evaluation in COMET. Journal of Cardiac Failure. 10(4). S84–S84.
17.
Metra, Marco, John G.F. Cleland, Michel Komajda, et al.. (2004). Should beta-blocker therapy be reduced or withdrawn in patients with worsening heart failure? insights from COMET. Journal of Cardiac Failure. 10(4). S77–S77.
18.
Poole‐Wilson, Philip A., Karl Swedberg, John G.F. Cleland, et al.. (2003). Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. The Lancet. 362(9377). 7–13.
19.
Lutiger, Beatrix, Karen Graham, Thomas R. Einarson, & Gideon Koren. (1992). Relationship Between Gestational Cocaine Use and Pregnancy Outcome. Obstetrical & Gynecological Survey. 47(4). 245–246.
20.
Lutiger, Beatrix, Karen Graham, Thomas R. Einarson, & Gideon Koren. (1991). Relationship between gestational cocaine use and pregnancy outcome: A meta‐analysis. Teratology. 44(4). 405–414.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Armin Scherhag Breakdown of academic impact, for papers by Andrzej Surdacki Breakdown of academic impact, for papers by Georg Wensing Breakdown of academic impact, for papers by Thomas Langenickel Breakdown of academic impact, for papers by George Klinger Breakdown of academic impact, for papers by Emmanuel Androulakis Breakdown of academic impact, for papers by K. H. Rahn Breakdown of academic impact, for papers by Michael Böhm Breakdown of academic impact, for papers by Hajime Nakahama Breakdown of academic impact, for papers by Mias Pretorius